These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 11067437)
1. Data confirm importance of health status adjustment. Capitation Rates Data; 2000 Jun; 5(6):64-5. PubMed ID: 11067437 [No Abstract] [Full Text] [Related]
2. The Pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation. Lamers LM; van Vliet RC Health Policy; 2004 Apr; 68(1):113-21. PubMed ID: 15033558 [TBL] [Abstract][Full Text] [Related]
3. Benefit trends work against providers managing drug risk. Capitation Rates Data; 2000 Mar; 5(3):34-6. PubMed ID: 11010134 [No Abstract] [Full Text] [Related]
6. Companies leaning on workers in battle against pharmacy costs. Diamond F Manag Care; 2002 Nov; 11(11):44-5. PubMed ID: 12491858 [No Abstract] [Full Text] [Related]
7. Health plans keeping drug cost increases in check with programs that promote generics. Capitation Manag Rep; 2002 Jul; 9(7):101-3, 97. PubMed ID: 12164057 [TBL] [Abstract][Full Text] [Related]
8. On the research status of risk-adjusted capitation rates. McClure W Inquiry; 1984; 21(3):205-13. PubMed ID: 6237054 [TBL] [Abstract][Full Text] [Related]
9. CRGs: a new risk adjustment tool for capitation management. Capitation Manag Rep; 2001 Sep; 8(9):129-32. PubMed ID: 11577499 [No Abstract] [Full Text] [Related]
10. Who foots the bill? HMOs confront the rising popularity of designer drugs. Shinkman R Mod Healthc; 1998 Jun; 28(26):162. PubMed ID: 10182332 [No Abstract] [Full Text] [Related]
12. Which risk adjustment model is right for you? Capitation Rates Data; 2002 Oct; 7(10):109-12. PubMed ID: 12412314 [No Abstract] [Full Text] [Related]
14. Prescribed cutback. HMOs shift risk to doc groups to curb drug utilization. Jaklevic MC Mod Healthc; 1997 Jul; 27(29):34. PubMed ID: 10168817 [No Abstract] [Full Text] [Related]
15. Capitated chronic disease management programs: a new market for pharmaceutical companies. Cave DG Benefits Q; 1995; 11(3):6-23. PubMed ID: 10151119 [TBL] [Abstract][Full Text] [Related]
16. Payment and provider profiling of episodes of illness of clinical illnesses involving rehabilitation. Goldfield N; Averill R; Eisenhandler J J Outcome Meas; 2000-2001; 4(3):706-20. PubMed ID: 11253904 [TBL] [Abstract][Full Text] [Related]
17. Fixing capitation's flaws: a view from the trenches. Capitation Manag Rep; 2000 Nov; 7(11):168-72. PubMed ID: 11188278 [No Abstract] [Full Text] [Related]
18. Blockbuster drugs coming off patent: will cap contracts benefit? Capitation Manag Rep; 2002 Apr; 9(4):56-8, 49. PubMed ID: 12004736 [TBL] [Abstract][Full Text] [Related]